CAV1 and neoplasm: For gedatolisib in combination with gefitinib, this additive effect was also verified by long-term colony-forming assays for HGSOC models expressing CAV1 and EGFR (Fig. 6d), as well as in long-term primary patient-derived organoid (PDO) cultures using early-passage tumor samples (Fig. 6e).